Balaxi Pharmaceuticals Ltd (BALAXI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 999933,
    "name": "Balaxi Pharma",
    "stock_name": "Balaxi Pharma",
    "full_name": "Balaxi Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/balaxi-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "24.49",
    "chg": 0.18,
    "chgp": "0.74%",
    "dir": 1,
    "prev_price": "24.31",
    "mcapval": "135.20 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "BALAXI",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 5,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE618N01022",
    "curr_date": "Jun 11, 01:09 PM",
    "curr_time": "13:27 PM",
    "last_traded_at": "Jun 11, 01:09 PM IST",
    "bse_nse_vol": 21665,
    "exc_status": "Active",
    "traded_date": "Jun 11, 2026",
    "traded_date_str": "2026 06 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/balaxi-pharma-999933-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Balaxi Pharmaceuticals Ltd Valuation Shifts to Very Expensive Amidst Weak Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-valuation-shifts-to-very-expensive-amidst-weak-returns-4029449",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_valuationdot_4029449.png",
        "date": "2026-06-02 08:04:36",
        "description": "Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant shift in its valuation parameters, moving from a previously attractive valuation to being classified as very expensive. This transformation is underscored by a sharp rise in its price-to-earnings (P/E) ratio and a contrastingly low price-to-book value (P/BV), raising questions about the stock’s price attractiveness relative to its historical and peer benchmarks."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4026014",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_mojoScore_4026014.png",
        "date": "2026-06-01 10:10:51",
        "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd Reports Sharp Decline in Quarterly Financial Performance Amid Negative Trend Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-reports-sharp-decline-in-quarterly-financial-performance-amid-negative-trend-shift-4024999",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_fintrenddot_4024999.png",
        "date": "2026-06-01 08:00:52",
        "description": "Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. The company’s recent quarterly results reveal a marked contraction in revenue and profitability, signalling a shift from a previously flat financial trend to a distinctly negative trajectory."
      },
      {
        "title": "Are Balaxi Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-balaxi-pharmaceuticals-ltd-latest-results-good-or-bad-4023875",
        "imagepath": "",
        "date": "2026-05-30 19:49:04",
        "description": "Balaxi Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.61 crores, which represents a substantial decline of 92.94% year-on-year. This decline is indicative of a broader trend, as the company has faced three consecutive quarters of revenue contraction, with Q4 FY26 revenue at ₹70.71 crores, down 7.29% from the previous year.\n\nThe operating margin has also experienced a dramatic contraction, falling to 0.17% from 16.47% year-on-year. This sharp decline highlights severe issues within the company's cost structure and operational efficiency. Furthermore, the operating profit before depreciation, interest, and tax (excluding other income) plummeted to just ₹0.12 crores, marking a staggering 99.04% decline compared to the same quarter last year.\n\nThe company's return on equity (ROE) has deteriorated to 6.09%, significant..."
      },
      {
        "title": "Balaxi Pharmaceuticals Q4 FY26: Profit Plunge and Margin Collapse Signal Deep Operational Distress",
        "link": "https://www.marketsmojo.com/news/result-analysis/balaxi-pharmaceuticals-q4-fy26-profit-plunge-and-margin-collapse-signal-deep-operational-distress-4022843",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalaxiPharmaceu_quaterlyResult_4022843.png",
        "date": "2026-05-29 22:23:58",
        "description": "Balaxi Pharmaceuticals Ltd. has reported deeply concerning Q4 FY26 results that reveal severe operational deterioration, with net profit collapsing 92.94% year-on-year to just ₹0.61 crores despite a ₹141.00 crore market capitalisation. The micro-cap pharmaceutical company's operating margin has virtually evaporated to a mere 0.17%, down from 16.47% in the same quarter last year, whilst revenue declined 7.29% to ₹70.71 crores. The stock has responded brutally to the company's sustained underperformance, plummeting 47.55% over the past year and trading 58.98% below its 52-week high of ₹63.90."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-hits-lower-circuit-amid-heavy-selling-pressure-4016897",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalaxiPharmaceu_stocks_hitting_lower_circuit_4016897.png",
        "date": "2026-05-27 13:00:08",
        "description": "At Rs 24.11, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 5% on 27 May 2026, with unfilled sell orders and a frozen price."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-sell-4002663",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalaxiPharmaceu_mojoScore_4002663.png",
        "date": "2026-05-21 10:10:58",
        "description": "Balaxi Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd Locks at Lower Circuit With 4.98% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-plunges-to-lower-circuit-amid-heavy-selling-pressure-3996936",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalaxiPharmaceu_stocks_hitting_lower_circuit_3996936.png",
        "date": "2026-05-18 11:00:17",
        "description": "At Rs 24.59, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 4.98% on 18 May 2026, with unfilled sell orders and a frozen price."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd Locks at Lower Circuit With 4.16% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-hits-lower-circuit-amid-heavy-selling-pressure-3985579",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalaxiPharmaceu_stocks_hitting_lower_circuit_3985579.png",
        "date": "2026-05-11 11:00:11",
        "description": "At Rs 28.41, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 5% on 11 May 2026, with unfilled sell orders and a frozen price."
      }
    ],
    "total": 114,
    "sid": "999933",
    "stock_news_url": "https://www.marketsmojo.com/news/balaxi-pharmaceuticals-999933"
  },
  "announcements": [
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Resignation of Mr Nidhin Jose as Chief Financial Officer of the company w.e.f. November 30, 2019.",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Resignation",
      "datetime": "21-Nov-2019"
    },
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Statement of deviation(s) or variation(s) under Reg. 32 of SEBI (LODR) Regulations 2015",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Statement of deviation(s) or variation(s) under Reg. 32",
      "datetime": "30-Oct-2019"
    },
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Board meeting held on October 29, 2019.",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Outcome of Board Meeting",
      "datetime": "29-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Balaxi Pharmaceuticals Ltd has declared <strong>5%</strong> dividend, ex-date: 01 Jul 22",
          "dt": "2022-07-01",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Balaxi Pharmaceuticals Ltd has announced <strong>2:10</strong> stock split, ex-date: 30 May 24",
          "dt": "2024-05-30",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Balaxi Pharmaceuticals Ltd Valuation Shifts to Very Expensive Amidst Weak Returns

2026-06-02 08:04:36

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant shift in its valuation parameters, moving from a previously attractive valuation to being classified as very expensive. This transformation is underscored by a sharp rise in its price-to-earnings (P/E) ratio and a contrastingly low price-to-book value (P/BV), raising questions about the stock’s price attractiveness relative to its historical and peer benchmarks.

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-06-01 10:10:51

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Read full news article

Balaxi Pharmaceuticals Ltd Reports Sharp Decline in Quarterly Financial Performance Amid Negative Trend Shift

2026-06-01 08:00:52

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. The company’s recent quarterly results reveal a marked contraction in revenue and profitability, signalling a shift from a previously flat financial trend to a distinctly negative trajectory.

Read full news article

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

2026-05-30 19:49:04

Balaxi Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.61 crores, which represents a substantial decline of 92.94% year-on-year. This decline is indicative of a broader trend, as the company has faced three consecutive quarters of revenue contraction, with Q4 FY26 revenue at ₹70.71 crores, down 7.29% from the previous year. The operating margin has also experienced a dramatic contraction, falling to 0.17% from 16.47% year-on-year. This sharp decline highlights severe issues within the company's cost structure and operational efficiency. Furthermore, the operating profit before depreciation, interest, and tax (excluding other income) plummeted to just ₹0.12 crores, marking a staggering 99.04% decline compared to the same quarter last year. The company's return on equity (ROE) has deteriorated to 6.09%, significant...

Read full news article

Balaxi Pharmaceuticals Q4 FY26: Profit Plunge and Margin Collapse Signal Deep Operational Distress

2026-05-29 22:23:58

Balaxi Pharmaceuticals Ltd. has reported deeply concerning Q4 FY26 results that reveal severe operational deterioration, with net profit collapsing 92.94% year-on-year to just ₹0.61 crores despite a ₹141.00 crore market capitalisation. The micro-cap pharmaceutical company's operating margin has virtually evaporated to a mere 0.17%, down from 16.47% in the same quarter last year, whilst revenue declined 7.29% to ₹70.71 crores. The stock has responded brutally to the company's sustained underperformance, plummeting 47.55% over the past year and trading 58.98% below its 52-week high of ₹63.90.

Read full news article

Balaxi Pharmaceuticals Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight

2026-05-27 13:00:08

At Rs 24.11, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 5% on 27 May 2026, with unfilled sell orders and a frozen price.

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Sell

2026-05-21 10:10:58

Balaxi Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Balaxi Pharmaceuticals Ltd Locks at Lower Circuit With 4.98% Loss — Sellers Queue, No Buyers in Sight

2026-05-18 11:00:17

At Rs 24.59, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 4.98% on 18 May 2026, with unfilled sell orders and a frozen price.

Read full news article

Balaxi Pharmaceuticals Ltd Locks at Lower Circuit With 4.16% Loss — Sellers Queue, No Buyers in Sight

2026-05-11 11:00:11

At Rs 28.41, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 5% on 11 May 2026, with unfilled sell orders and a frozen price.

Read full news article

View All News